OS
SECONDARY
At the interim analysis, 318 out of 507 (62.7%) patients had died: 144 of the 254 (56.7%) patients randomized to receive zolbetuximab, and 174 of the 253 (68.8%) patients randomized to receive placebo. OS as a key secondary endpoint was statistically significantly prolonged in patients in the zolbetuximab arm versus the placebo arm (median, 14.39 months versus 12.16 months, respectively; HR = 0.771; 95% CI, 0.615–0.965; 